Spektar Therapeutics and Altus Formulation Inc. announced the launch of Spektus Pharma Inc. a new Canadian specialty pharma company developing patent-protected value-added medicines for the growing CNS segment.
Focusing first on the psychiatry space, the new company combines the commercial acumen of Spektar with the pharmaceutical expertise of Altus to generate a portfolio of novel and differentiated therapies that address the unmet needs of different patient segments. Each new product leverages Flexitab breakable extended-release technology to provide clinically meaningful benefits to the patient backed by new label claims. Supported by robust patents, Spektus products are designed to meet the commercial challenges facing global markets today while addressing the competing demands of patients, healthcare providers and payers. Spektus products are commercialized via regional licensing agreements with leading pharma companies around the world.
Dr. Damon Smith, CEO Altus Formulation, said: After working with Spektar for a number of very successful years, we’re delighted to combine our skill sets with theirs to form this exciting new venture. By doing so, the new company can provide fully developed, de-risked cost-effective products to global partners.
Mr. Zarvaan Merchant, CEO Spektar Therapeutics, said: The Flexitab platform has tremendous potential to improve the delivery of existing drugs in the CNS segment and beyond. We are excited to join hands with our partners at Altus to deliver a portfolio of value-added medicines that serve the needs of patients with serious mental health challenges.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!